Molecular hallmarks of androgen receptor targeting in prostate cancer

在肿瘤学药物开发中，迫切需要更好的生物标志物来响应前列腺癌治疗，在临床上帮助治疗决策，在临床前促进新兴药物进入临床实践。使用独特的外植体培养模型，该项目将确定可用于准确和可靠地评估人类前列腺癌对雄激素受体(AR)靶向治疗的反应的蛋白质和脂肪标记物。对这些生物标记物的识别和功能评估将确定那些可以在临床试验中用作替代终点的生物标记物，促进研究试剂的及早批准，并导致前列腺癌治疗管理的改进选择。

There is a critical need in oncology drug development for better biomarkers of response to prostate cancer therapies, clinically to assist with treatment decision making, and pre-clinically to facilitate translation of emerging agents into clinical practice. Using a unique explant culture model, this project will identify protein and lipid markers that can be used to accurately and reliably assess response to androgen receptor (AR)-targeting therapies in human prostate tumours. The identification and functional assessment of these biomarkers will identify those that can be used as surrogate endpoints in clinical trials, facilitate earlier approval of investigational agents and lead to improved options for therapeutic management of prostate cancer.